Distribution of factors by treatment assignment
| Factor . | GM-CSF . | Placebo . | ||
|---|---|---|---|---|
| Ara-C . | Ara-C+M . | Ara-C . | Ara-C+M . | |
| Age 60-69 years | 19 | 20 | 25 | 32 |
| 70 or older | 18 | 22 | 20 | 13 |
| WBC | ||||
| 0.2-3.0 | 11 | 13 | 22 | 16 |
| 3.1-30.0 | 14 | 17 | 16 | 13 |
| 30.1 or more | 12 | 11 | 6 | 14 |
| Platelet level | ||||
| 4-50 | 11 | 13 | 17 | 16 |
| 51-99 | 14 | 10 | 11 | 10 |
| 100 or more | 12 | 18 | 16 | 17 |
| Cytogenetics | ||||
| CBF | 3 | 1 | 0 | 2 |
| Other | 13 | 7 | 11 | 9 |
| Normal | 5 | 21 | 13 | 18 |
| Immunophenotype | ||||
| CD56− | 10 | 23 | 19 | 17 |
| CD56+ | 2 | 2 | 0 | 2 |
| Factor . | GM-CSF . | Placebo . | ||
|---|---|---|---|---|
| Ara-C . | Ara-C+M . | Ara-C . | Ara-C+M . | |
| Age 60-69 years | 19 | 20 | 25 | 32 |
| 70 or older | 18 | 22 | 20 | 13 |
| WBC | ||||
| 0.2-3.0 | 11 | 13 | 22 | 16 |
| 3.1-30.0 | 14 | 17 | 16 | 13 |
| 30.1 or more | 12 | 11 | 6 | 14 |
| Platelet level | ||||
| 4-50 | 11 | 13 | 17 | 16 |
| 51-99 | 14 | 10 | 11 | 10 |
| 100 or more | 12 | 18 | 16 | 17 |
| Cytogenetics | ||||
| CBF | 3 | 1 | 0 | 2 |
| Other | 13 | 7 | 11 | 9 |
| Normal | 5 | 21 | 13 | 18 |
| Immunophenotype | ||||
| CD56− | 10 | 23 | 19 | 17 |
| CD56+ | 2 | 2 | 0 | 2 |
GM-CSF indicates granulocyte-macrophage colony-stimulating factor; Ara-C, cytarabine; M, mitoxantrone; WBC, white blood cell count; CBF, core binding factor.